Cubist Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Cubist Pharmaceuticals's estimated annual revenue is currently $49.6M per year.(i)
  • Cubist Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Cubist Pharmaceuticals has 247 Employees.(i)
  • Cubist Pharmaceuticals grew their employee count by -6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M344-2%$634MN/A
#2
$49.6M247-6%N/AN/A
#3
$10.7M53130%N/AN/A
#4
$20.1M10821%$113MN/A
#5
$4M48118%N/AN/A
#6
$1.8M4063%$538MN/A
#7
$40.2M200-11%N/AN/A
#8
$11.6M192-14%$506.4MN/A
#9
$3.7M4588%N/AN/A
#10
$4360M45081175%N/AN/A

Effective January 22, 2015, Cubist Pharmaceuticals is now a wholly owned subsidiary of Merck & Co., Inc. For continued news and updates, we encourage you to follow Merck on LinkedIn at https://www.linkedin.com/company/merck to stay in touch and learn more.

keywords:N/A

N/A

Total Funding

247

Number of Employees

$49.6M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cubist Pharmaceuticals News

2022-04-19 - Movers & Shakers: John Maraganore, Larry Alstiel, Brad ...

Previously, she was the COO at Dimension Therapeutics. Before that, she held several executive level roles at Cubist Pharmaceuticals,...

2022-04-17 - Leadership transition at Cerevance

Prior to Tetraphase, he was chief commercial officer for Trius Therapeutics, which was acquired by Cubist Pharmaceuticals for more than $700...

2022-04-17 - Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases

... in the biotech and pharmaceutical industries to the company. ... was acquired by Cubist Pharmaceuticals for more than $700 million.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$56.3M2471%N/A
#2
$40.9M24815%N/A
#3
$49.5M250N/AN/A
#4
$41M257-6%N/A
#5
$78.4M2645%N/A